Reuters
Published Feb 19, 2021 11:01
By Kate Kelland
LONDON, Feb 19 (Reuters) - Rich countries are on course to have over a billion more doses of COVID-19 vaccines than they need, leaving poorer nations scrambling for leftover supplies as the world seeks to curb the coronavirus pandemic, a report by anti-poverty campaigners found on Friday.
In an analysis of current supply deals for COVID-19 vaccines, the ONE Campaign said wealthy countries, such as the United States and Britain, should share the excess doses to "supercharge" a fully global response to the pandemic.
The advocacy group, which campaigns against poverty and preventable diseases, said a failure to do so would deny billions of people essential protection from the COVID-19-causing virus and likely prolong the pandemic.
The report looked specifically at contracts with the five leading COVID-19 vaccine makers - Pfizer (NYSE:PFE) PFE.N -BioNTech, Moderna, Oxford-AstraZeneca AZN.L , Johnson & Johnson (NYSE:JNJ) JNJ.N , and Novavax NVAX.O .
It found that to date, the United States, the European Union, Britain, Australia, Canada and Japan have already secured more than 3 billion doses - over a billion more than the 2.06 billion needed to give their entire populations two doses.
"This huge excess is the embodiment of vaccine nationalism," said Jenny Ottenhoff, ONE Campaign's senior director for policy.
"Rich countries understandably hedged their bets on vaccines early in the pandemic but with these bets paying off in spades, a massive course correction is needed if we are going to protect billions of people around the world," she added.
The analysis found that, along with other COVID vaccine supplies procured by the global COVAX vaccine-sharing plan and in bilateral deals, the excess rich-country doses would go a long way to protecting vulnerable people in poorer countries.
This would significantly reduce the risk of deaths from COVID-19, it said, as well as limiting the chances of new virus variants emerging and accelerating an end to the pandemic.
The World Health Organization on Thursday urged nations with vaccines not to share them unilaterally, but to donate them to the global COVAX scheme to ensure fairness. One Campaign report found that with current supply deals, the following excess doses would be available for wealthy countries to share:
Country
Population Doses
100% coverage Doses
(total)
Purchased* (2-doses)
available
to share
Australia 25,364,310 114,800,000 50,728,620
64,071,380
Canada
37,589,260 190,000,000 75,178,520
114,821,480
Japan
126,264,930 290,000,000 252,529,860
37,470,140
United
66,834,400 247,000,000 133,668,800
113,331,200
Kingdom
United
328,239,520 1,110,000,0 656,479,040
453,520,960
States
00
European 447,512,040 1,360,000,0 895,024,080
464,975,920
Union
00
TOTAL
1,248,191,080
* Of the five leading COVID-19 vaccines
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.